CTOs on the Move

Makindus

www.makindus.com

 
Makindus is a privately-held, specialty pharmaceutical development company focused on ophthalmology and rare diseases. The Company`s lead product candidate is MI-100, a novel ophthalmic formulation of a legacy compound being developed for Stargardt disease, a rare form of juvenile macular degeneration that occurs in approximately 1 in 10,000 individuals. Makindus has met with the FDA and EMA, and is in the final stages of planning a Phase 3 clinical trial program. The Company is seeking partners and additional sources of funding and collaboration for the development program of MI-100 for Stargardt disease.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.makindus.com
  • 3805 Old Easton Road
    Doylestown, PA USA 18902
  • Phone: 267.291.4912

Executives

Name Title Contact Details

Similar Companies

NationalAccessCannabis

We are dedicated to health and to working in consultation with health professionals. We are committed to responsibility, through our secure non-transferable medical cannabis access card system. A system we are establishing in consultation with law enforcement to achieve national recognition.

ParaTechs

ParaTechs is a Lexington, KY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Molecular Toxicology

Molecular Toxicology is a Boone, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Switch Therapeutics

Switch Therapeutics is an emerging preclinical stage biotechnology company pioneering a new type of medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science with the goal of treating a range of diseases – affecting the central nervous system and systemic indications – with significant unmet needs. Switch`s novel gene knockdown approach is based on technology developed by renowned researchers in the field of RNA from Caltech, Harvard and City of Hope. Based on the scientific discovery of Switch`s co-founders, the company has developed a novel proprietary platform known as CASi (Conditionally Activated siRNAs) that combines advantageous properties of both single and double-stranded RNAs in a single molecule, allowing for cell selective RNAi activity. To date, Switch has raised $52M in funding through Series A, and the company`s South San Francisco based team has continued to grow as its research has advanced.

ProteoCell Biotechnologies

ProteoCell Biotechnologies Inc. is a Laval, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.